[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,57,82,104,126,155,189,216,244,261,282,312,342,376,394,419,451,476,497,514,532,558,586,611,640],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100598968","a-study-to-evaluate-the-safety-and-effectiveness-of-the-rapidlink-device-when-used-in-patients-undergoing-an-open-surgical-procedure-to-repair-the-aorta-100598968",false,"NCT07078383","A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta","Evaluation of the Rapidlink Device for Use in the Repair or Replacement of the Supra-Aortic Vessels During an Open Surgical Procedure of the Thoracic Aorta","RAPID","Inclusion Criteria:\n\n* Patient is aged 18 years or over on date of consent\n* Written informed consent (from patient or a legally authorized representative) to participate in study, documenting willingness and ability to comply with all study procedures and study visits (unless an exemption for emergency cases has been IRB \u002F EC approved)\n* Patient's need for open surgical repair of the thoracic aorta using a Gelweave graft or a Thoraflex Hybrid device (AnteFlo or Plexus) in line with the applicable IFU\n* Anticipated need to use Rapidlink for the repair or replacement of the LSA, LCCA and\u002For IA during the open surgical repair\n* Patient has an 8-15 mm inner diameter (target SAV)\n* The diameters of the patient's target supra-aortic vessel(s), fall within the ranges specified in the IFU\n\nExclusion Criteria:\n\n* Patient does not have a clear landing zone equal to the implantable stent length which is free from stenosis, calcification or thrombus.\n* Patient does not have a sealing zone free from tortuosity.\n* Patient has significant angulation (\\>79° with an internal radius of less than 6mm) for the full implantable stent length\n* Patient cannot receive anticoagulation \u002F antiplatelet therapy during or after the index procedure as per the protocol\n* Patient has uncontrolled hypercoagulation\n* Patient has a condition which may compromise or prevent the necessary imaging requirements\n* Patient has anatomic variants which would compromise circulation to the first branch off the target artery after placement of the Rapidlink device (unless planned and\u002For otherwise revascularized)\n* Patient is unfit for open surgical repair involving circulatory arrest per the study investigator\n* Patient has known sensitivity to polyester, nitinol, tantalum, or materials of bovine origin\n* Patient has a ruptured aorta\n* Patient has active endocarditis or an active infective disorder of the aorta\n* Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure\n* Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study\n* Patient is female and is pregnant or planning to become pregnant during the course of the study. Females of childbearing potential must use acceptable methods of contraception during the course of the study.\n* Patient has an uncorrectable bleeding anomaly\n* Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.5mg\u002FdL)\n* Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated\n* Patient has a co-morbidity causing expected survival to be less than 1 year\n* Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure\n* Patient has a known chronic aortic dissection involving the intended landing zone of the target supra-aortic vessel(s)","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Goal of this Clinical Study is to evaluate the safety and effectiveness of the Rapidlink device in the repair or replacement of the supra-aortic vessels during open surgical repair of aortic disease affecting the thoracic aorta.\n\nThis study will collect information on patients who are already having surgery to repair their aorta and who will have Rapidlink device implanted into one or more of the aortic arch vessels.\n\nThe first 32 subjects enrolled will undergo left subclavian artery repair or replacement, only, with the Rapidlink device. After the 32nd subject, enrollment will proceed to include subjects undergoing any supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and\u002For innominate artery) repair or replacement with the Rapidlink device in a planned surgery.\n\nAfter the 32nd subject is enrolled in the main group, up to 30 subjects will undergo supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and\u002For innominate artery) repair or replacement with the Rapidlink device in an emergency setting.\n\nData will be collected before, during and after surgery including recovery at discharge, 30 days, 6 months, 1 and 2 years after the surgery.",[27,28,29,30,31,32],"Aortic Aneurysm","Aortic Aneurysm and Dissection","Aortic Diseases","Aneurysm of Aorta, Thoracic","Aneurysmal Disease","Aorta, Thoracic Pathologies",[34,35,36,37,38,39,40,41,42,43],"Vascular Prosthesis","Replacement or bypass of disease vessels","aneurysmal disease","Aortic branch vessels","Open aortic arch repair","aneurysm","dissection","Supra-aortic Vessels","Frozen Elephant Trunk","Left Subclavian Artery","RECRUITING","2026-07-01",{"date":47,"type":48},"2026-07-02","ACTUAL",{"date":50,"type":48},"2025-12-19",{"date":52,"type":21},"2028-11",{"name":54,"class":55},"Vascutek Ltd.","INDUSTRY",22,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100644344","construction-of-a-prospective-cohort-database-for-the-perioperative-period-of-cardiac-surgery-100644344","NCT07662317","Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031\n\nExclusion Criteria:\n\n* Refusal to provide informed consent",{"count":64,"type":21},10000,"OBSERVATIONAL","Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.\n\nThis muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.\n\nThis database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.",[68,69,70,29],"Valve Heart Disease","Coronary Artery Disease","Coronary Heart Disease","2026-06-22",{"date":73,"type":48},"2026-06-23",{"date":75,"type":21},"2026-06-25",{"date":77,"type":21},"2032-05-31",{"name":79,"class":80},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100617768","intervascular-post-market-clinical-follow-up-pmcf-registry-100617768","NCT07322913","Intervascular Post-Market Clinical Follow-Up (PMCF) Registry","Post-Market Clinical Follow-up Registry to Evaluate the Safety and Performance of the Intervascular Vascular Grafts and Patches in Patients Undergoing Bypass, Replacement, or Repair of Aortic, Peripheral, or Carotid Arteries","Inclusion Criteria:\n\n* Willing, and able to provide legally-effective written informed consent (as required by Institutional Review Board or Ethics Committee)\n* Male and female patients that have undergone bypass, replacement or repair of the peripheral arteries, aorta, or carotid artery using the Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy)\n* Were at least 18 years of age at the time of the procedure\n* Available records for data collection with a minimum of 3 years (36 months) of data\u002Ffollow-up.\n\nExclusion Criteria:\n\n* Active infection in the region of device placement at the time of implantation of the Intergard Standard and Hemashield Vascular Graft or Patch.",{"count":90,"type":21},1200,"The purpose of this registry is to evaluate the long-term safety and performance of Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy) for bypass, repair or replacement of aortic, peripheral, or carotid arteries. This registry is intended to further define the expected product lifetime of the devices and to collect data related to usefulness of the antimicrobial coatings.",[93,29,94],"Carotid Artery Diseases","Peripheral Arterial Diseases","2026-06-12",{"date":97,"type":48},"2026-06-15",{"date":50,"type":48},{"date":100,"type":21},"2026-12",{"name":102,"class":55},"Intervascular",4,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":81},"100629785","impact-of-aortic-diseases-on-quality-of-life-and-work-ability-100629785","NCT07479186","Impact of Aortic Diseases on Quality of Life and Work Ability","Impact of Aortic Disease on Patients' Quality of Life and Working Capacity","IMPACT-A","Inclusion Criteria:\n\n* Male and female patients with a confirmed diagnosis of aortic disease under the care of the Complex Operative Unit of Vascular Surgery of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS.\n* Patients aged between 18 and 70 years.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 70 years.\n* Incomplete diagnostic workup.\n* Patients who have undergone surgical procedures or experienced concomitant acute events unrelated to the aorta, with a predominant and recent functional impact, that make it impossible to isolate the effect of aortic disease on return to work.","70 Years",{"count":114,"type":21},300,"Aortic diseases encompass a wide spectrum of congenital and acquired, acute and chronic conditions, characterized by high clinical and prognostic complexity. The aorta plays a central role in blood flow distribution and hemodynamic modulation owing to its elastic properties, which become progressively impaired with aging and in the presence of genetic or degenerative factors. Beyond clinical outcomes, aortic diseases lead to a marked reduction in health-related quality of life, psychological well-being, and functional capacity, with significant occupational and social consequences, thereby making multidisciplinary management necessary. This longitudinal observational study aims to systematically assess health-related quality of life, fatigue, psychological well-being, and work ability in patients with aortic diseases, with the objective of providing objective bases for occupational risk evaluation and promoting an interdisciplinary management model that integrates clinical, psychological, and work-related aspects, thereby supporting the maintenance or recovery of work functioning.",[29],"2026-06-05",{"date":119,"type":48},"2026-06-09",{"date":121,"type":48},"2026-03-31",{"date":123,"type":21},"2028-06-30",{"name":125,"class":80},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105","NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness",{"count":134,"type":21},80,[24],"The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[138,139,140,29,141,27,142,143,144],"CAD - Coronary Artery Disease","CABG","Valve Disease, Heart","Valve Heart Stenosis","Mitral Disease","AORTIC VALVE DISEASES","Aortic Dissection","NOT_YET_RECRUITING","2026-05-11",{"date":148,"type":48},"2026-05-14",{"date":150,"type":21},"2026-05-31",{"date":152,"type":21},"2027-05-30",{"name":154,"class":80},"Shih,Wen-Chi",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":65,"phases":4,"briefSummary":167,"conditions":168,"keywords":178,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":81},"100489526","development-of-circ-technologies-100489526","NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",true,{"count":165,"type":21},1000,"20 Years","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[169,170,171,172,173,174,175,29,176,177],"Cardiovascular Diseases","Heart Failure","Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Atrial Fibrillation","Ventricular Fibrillation",[179],"MRI","2026-05-06",{"date":182,"type":48},"2026-05-08",{"date":184,"type":48},"2022-09-09",{"date":186,"type":21},"2042-09-09",{"name":188,"class":80},"The Cleveland Clinic",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100578837","inflate-study-investigation-of-the-safety-and-performance-of-a-novel-ptv-balloon-in-patients-undergoing-tavi-for-severe-aortic-stenosis-100578837","NCT06816485","INFLATE Study: Investigation of the Safety and Performance of a Novel PTV Balloon in Patients Undergoing TAVI for Severe Aortic Stenosis","Investigation of the Safety and Performance of a Novel PTV Balloon in Patients Undergoing TAVI for Severe Aortic Stenosis","Inclusion Criteria:\n\n1. Symptomatic severe calcific stenosis of a native aortic valve with an AVA ≤1.0 cm2 (or AVA index ≤0.6 cm2\u002Fm2) AND mean aortic pressure gradient ≥ 40mmHg OR maximal transaortic velocity ≥4.0m\u002Fs OR Doppler velocity index ≤0.25 on site-reported echocardiography\n2. Local multi-disciplinary Heart Team agrees on indication and eligibility for TAVI\n3. Age ≥18 years\n4. Patient has signed the Patient Informed Consent Form\n5. Patient is willing and able to comply with requirements of the study\n6. Patients planned for trans-femoral procedure\n\nExclusion Criteria:\n\n1. Mean aortic annulus diameter as measured by pre-procedural CT or internal diameter of the bioprosthesis is \\\u003C16 mm or \\>30 mm\n2. Echocardiographic evidence of intracardiac thrombus, mass or vegetation (site-reported)\n3. Significant disease of the aorta that would preclude safe advancement of the TAVI system\n4. Severe ilio-femoral vessel disease that would preclude safe performance of the TAVI procedure\n5. Severe tricuspid regurgitation and\u002For failing right heart (site-reported)\n6. Severe left ventricular dysfunction with ejection fraction (EF) \\\u003C20% (site-reported)\n7. Evidence of active endocarditis or other acute infections\n8. Renal failure requiring continuous renal replacement therapy\n9. Untreated clinically significant coronary artery disease requiring revascularization\n10. Acute MI ≤30 days prior to the index procedure\n11. Symptomatic carotid or vertebral artery disease requiring intervention or carotid\u002Fvertebral intervention within the preceding 45 days\n12. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) ≤6 months or prior CVA with moderate or severe disability (e.g. modified Rankin scale score \\>2)\n13. History of bleeding diathesis or coagulopathy; acute blood dyscrasias as defined: thrombocytopenia (platelets \\\u003C80,000\u002Fµl), acute anemia (hemoglobin \\\u003C10 g\u002Fdl), leukopenia (WBC \\\u003C3000\u002F µl)\n14. Severe (greater than 3+) mitral insufficiency (site-reported)\n15. Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or to bovine tissue\n16. Currently participating in another investigational drug or device study\n17. Pregnancy or intend to become pregnant during study participation\n18. Unicuspid aortic valve\n19. Non-calcified aortic stenosis\n20. Identified high risk of coronary occlusion due to Sinus of Valsalva anatomy and\u002For bulky calcified aortic valve leaflets in close proximity to coronary ostia\n21. Isolated Aortic Insufficiency\n22. Patients with a permanent pacemaker\n23. Patients with pre-existing LBBB, RBBB and AV block 2 and 3",{"count":197,"type":21},93,[24],"This clinical investigation is being done to evaluate the safety and effectiveness of a new device, a PTV Balloon, that will be used to open up an area in the heart (the valve) before and potentially after placing a new valve in patients requiring a new heart valve.\n\nThe main question it aims to answer is:\n\nWhat percentage of patients develop new heart conduction problems after using the investigational PTV Balloon for pre-dilatation?\n\nParticipants will:\n\n1. Undergo a TAVI procedure, where the PTV Balloon will be used for pre-dilatation and may also be used for post-dilatation.\n2. Will be followed up until discharge or up to 7 days, whichever happens first.",[29],[202,203,204,205],"PTV Balloon","TAVI","Aortic Valve Stenosis","Balloon Aortic Valvuloplasty","2026-04-15",{"date":208,"type":48},"2026-04-16",{"date":210,"type":48},"2025-12-15",{"date":212,"type":21},"2026-08",{"name":214,"class":55},"Biosensors Europe SA",9,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100506919","use-of-shockwave-m5l6-ivl-catheter-intravascular-lithotripsy-in-hostile-and-calcified-iliac-access-100506919","NCT05880641","Use of Shockwave M5+\u002FL6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access","No-profit, Pilot, Observational, Multicentric, Prospective Study on the Use of Shockwave M5+\u002FL6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access to Facilitate Aortic Endovascular Repair. SHOCK-ACCESS STUDY.","SHOCK-ACCESS","Inclusion Criteria:\n\n* Age ≥18 years old;\n* Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study;\n* Patient presenting with aortic disease indicated for endovascular treatment considered unfeasible based on severely calcified iliac access and outer diameter of the \"ideal\" aortic endograft at onset of the procedure (considering the main body and\u002For contralateral limb in case of iliac distal landing zone);\n* Patients presenting a ratio \\> 0.2 between outer diameter of the aortic stent graft delivery system (OD-SG) and minimum lumen diameter (MLD); decision concerning SG will be taken balancing the lower profile on the market and the better graft fit for patient's anatomy;\n* Patients presenting calcium grade 3 or 4 accordingly to 360° coronary classification (grade 1 = 0-90°, grade 2 = 90°-180°; grade 3 = 180°-270°; grade 4 = 270°-360°);\n* Patients presenting a lesion length \\> 20 mm, intended as the sum of all calcified iliac lesions between two endpoints, from the aortic bifurcation up to the proximal common femoral artery (CFA);\n* Patients eligible for treatment with Shockwave M5+ IVL device;\n* Patients presenting with aortic disease indicated for endovascular treatment associated or not to aorto-iliac occlusive disease (Rutherford classification score II - VI for chronic limb ischemia);\n* Patients compliant with the conduct of follow-up visits according to the timelines specified in the protocol.\n\nExclusion Criteria:\n\n* Bilateral Iliac Occlusion;\n* Urgent setting with presence of iliac thrombus (acute limb ischemia);\n* Any patient considered to be hemodynamically unstable at procedure onset;\n* Patients refusing treatment;\n* Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated;\n* Patients with a history of prior life-threatening contrast medium reaction;\n* Life expectancy of less than twelve months.",{"count":225,"type":21},40,"The study will evaluate, in a controlled setting, the efficacy and safety of the intravascular lithotripsy using Shockwave™ M5+\u002FL6 Peripheral Intravascular Lithotripsy Catheter to facilitate delivery of aortic large-bore devices in iliac calcified access.",[29,228,229],"Aorto-Iliac Atherosclerosis","Peripheral Arterial Disease",[231,232,233],"Aortic Disease","Intravascular Lithotripsy","Hostile Access","2026-03-23",{"date":236,"type":48},"2026-03-25",{"date":238,"type":48},"2023-06-26",{"date":240,"type":21},"2027-09",{"name":242,"class":80},"EndoCore Lab s.r.l.",6,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":163,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":165,"type":21},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[169,170,171,172,173,174,175,29,176,177],[179],"2026-03-19",{"date":234,"type":48},{"date":257,"type":21},"2026-04",{"date":259,"type":21},"2037-08",{"name":188,"class":80},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":163,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":166,"studyType":65,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100362959","montalcino-aortic-consortium-precision-medicine-for-heritable-thoracic-aortic-disease-100362959","NCT04005976","Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease","MAC:H-TAD","Inclusion Criteria:\n\n* Patients and their relatives with a confirmed pathogenic, likely pathogenic variant, or variant of unknown clinical significance in at least one of the H-TAD genes (i.e. TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLK, PRKG1, MAT2A, MFAP5, LOX, COL3A1, FOXE3, and FBN1).\n* Patients of all ages, sex and race for which informed consent can be obtained.\n\nExclusion Criteria:\n\n* Patients without a confirmed causative variant for H-TAD.",{"count":269,"type":21},5000,"The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.",[27,144,29],"2026-01-29",{"date":274,"type":48},"2026-02-02",{"date":276,"type":48},"2016-06-15",{"date":278,"type":21},"2037-01-01",{"name":280,"class":80},"The University of Texas Health Science Center, Houston",20,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":289,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":292,"conditions":293,"keywords":300,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":103},"100565112","comparison-of-the-diagnosis-time-of-vet-and-scl-in-patients-with-intraoperative-coagulopathy-100565112","NCT06637943","Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy","Comparison of Time Taken for Diagnosing Intraoperative Coagulopathies: Point-of-care Viscoelastic Tests vs Standard Central Laboratory Tests","Inclusion Criteria:\n\n* patients who will undergo elective surgery with a high risk of moderate to severe amount of intraoperative bleeding or coagulopathy (e.g., cardiac surgery, joint replacement, spine surgery, hepatectomy, radical prostatectomy)\n* patients who provide written informed consent\n* patients who may warrant the intraoperative use of POC viscoelastic test or SCL test\n\nExclusion Criteria:\n\n* pregnancy\n* withdrawal of consent\n* termination of surgery without performing either POC viscoelastic test or SCL tests\n* when the study conductor deems it inappropriate to proceed with the protocol with the patient","19 Years",{"count":291,"type":21},210,"The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients with intraoperative bleeding.",[294,295,296,297,298,299,171,29],"Arthritis of Knee","Arthritis of Hip","Spine","Prostate Cancer","Hepatic Cancer","Valvular Disorder",[301,302,303],"viscoelastic test","standard central laboratory test","coagulation","2025-12-01",{"date":306,"type":48},"2025-12-08",{"date":308,"type":21},"2026-02-01",{"date":150,"type":21},{"name":311,"class":80},"Konkuk University Medical Center",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100569099","trial-of-the-f2-filter-and-delivery-system-for-embolic-protection-during-tavr-100569099","NCT06689839","Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR","A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection System Vs. Standard of Care (Unprotected or Sentinel® Cerebral Protection System) During Transfemoral Transcatheter Aortic Valve Replacement","SHIELD","Key Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Patient meets the established criteria and indications for commercially available TAVR via transfemoral access and is scheduled to undergo TAVR per their treating physician.\n* Patient is willing and able to comply with protocol-specified follow-up evaluations.\n* Patient is able and willing to provide written informed consent.\n* Patient meets all criteria for use of control device (Sentinel device, per IFU).\n\nKey Exclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n* Patient requires an urgent or emergent TAVR procedure.\n* Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure or planned within 30 days post-TAVR procedure.\n* Diagnostic cardiac catheterization within 10 days prior to TAVR procedure.\n* Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure.\n* Prior prosthetic heart valve in any position.\n* Known intracardiac thrombus.\n* Active infection or endocarditis.\n* Patient is contraindicated for anti-platelet and\u002For anticoagulant therapy.\n* Patient refuses blood transfusion.\n* Renal insufficiency (creatinine \\> 2.5 mg\u002FdL or GFR \\\u003C 30) and\u002For renal replacement therapy at the time of screening.\n* Patients with hepatic failure (Child-Pugh class C).\n* Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) \\\u003C 30%.\n* Females who are pregnant or nursing or plan to become pregnant during their participation in the study.\n\nNeurological Exclusion Criteria:\n\n* Modified Rankin Scale (mRS) ≥ 2 at screening.\n* Cerebrovascular event including TIA within 6 months of the procedure.\n* Patient has active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.\n* Patient has severe visual, auditory, or learning impairment.\n* Patient has neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.\n\nMagnetic Resonance Imaging Exclusion Criteria:\n\n* Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).\n* High risk of complete AV block after TAVR, with the need of permanent pacemaker.\n* Claustrophobia precluding MRI scanning.\n\nAnatomical and CT Exclusion Criteria:\n\n* Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment.\n* Presence of cardiovascular implant in aorta and\u002For peripheral access vessels.\n* Access vessels with excessive tortuosity.\n* Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous.","50 Years",{"count":322,"type":21},500,[24],"The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)",[326,29],"Aortic Stenosis Treated With TAVI",[328,329,330,204,331],"Embolic Protection","Transcatheter Aortic Valve Replacement","TAVR","Aortic Valve Diseases","2025-11-19",{"date":334,"type":48},"2025-11-20",{"date":336,"type":48},"2025-09-09",{"date":338,"type":21},"2027-01",{"name":340,"class":55},"EnCompass Technologies, Inc.",10,{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":355,"conditions":356,"keywords":360,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":81},"100513941","phase-4-liposomal-bupivacainebupivacaine-in-rectus-sheath-blocks-versus-ropivacaine-in-rectus-sheath-blocks-and-catheters-100513941","NCT05972018","Liposomal Bupivacaine\u002FBupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters","Liposomal Bupivacaine\u002FBupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Versus Ropivacaine in Bilateral Rectus Sheath Blocks And Catheters With Intermittent Hourly Boluses.","EXODUS","Inclusion Criteria:\n\n1. Patients aged 18-80 years\n2. Patients scheduled for elective vascular surgery with an open mid-abdominal laparotomy incision, including abdominal aortic aneurysm repair surgery (AAA), mesenteric artery bypass surgery, and aortobifemoral bypass surgery for aortic occlusive disease.\n3. Patients who are able to speak and read English\n4. Patients with American Society of Anesthesiology (ASA) physical status score I-IV\n5. Patients who are admitted to the hospital and are incidentally discovered to require any of the aforementioned surgeries, being asymptomatic for vascular issues, and having their surgery scheduled no sooner than three days after admission, are also considered eligible.\n\nExclusion Criteria:\n\n1. Emergency vascular reconstruction surgery., patients admitted to the hospital due to symptoms directly associated with their vascular condition, such as severe abdominal pain or a ruptured aneurysm causing bleeding, will be excluded.\n2. Patients with contraindications to RSB, including but not limited to anatomical abnormality, previous surgical intervention that limits or prevents receiving bilateral RSBs, or infection at the injection site.\n3. History of allergy to local anesthetics.\n4. Weight \\\u003C 40 kg, as a combination of 20 mL of Bupivacaine 0.25% with 30 mL of LB is greater than the maximal dose allowed, given concern for local anesthetic toxicity.\n5. Patients who take long-acting opioid medication, or on continuous opioid use \\> 50 MME per day for at least 30 days within 90 days prior to surgery.\n6. Patients who have chronic pain syndrome with a recent preoperative consultation with the chronic pain service. Also, patients with distant metastatic cancers (e.g. bone, lung, brain) confirmed by CT scan.\n7. Patients with current substance abuse, or history of substance abuse within 3 months, this includes any illicit drugs (not including marijuana) or excessive alcohol consumption as defined as 4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men.\n8. Lack or refusal to sign the study consent.\n9. Patients who are unable to receive postoperative ropivacaine intermittent boluses within the first 5 days after surgery due to issues with their catheter (such as dislodgement, migration, or kinking) will be excluded from the final analysis.\n10. Patients with a plan to undergo abdominal wall surgery, in addition to the vascular surgery that involves a mid-abdomen incision, such as abdominal wall reconstruction surgery. The additional abdominal wall incisions or interventions might have an impact on the study's pain, opioid, and LOS outcomes.","80 Years",{"count":352,"type":21},14,[354],"PHASE4","The goal of this pilot study is to compare single shot rectus sheath blocks of liposomal bupivacaine\u002Fbupivacaine mixture to bilateral rectus sheath catheters infused with ropivacaine (standard of care at our facility) in patients undergoing vascular surgery with an open mid-abdominal laparotomy incision. This study will assess the safety and feasibility of this approach compared to standard of care.\n\nParticipants will receive either a single dose of liposomal bupivacaine\u002Fbupivacaine mixture intraoperatively at the end of surgery through bilateral rectus sheath blocks (LB\u002FB group) or the standard of care ropivacaine intraoperatively at the end of surgery through bilateral rectus sheath blocks with the insertion of bilateral RS catheter for continuous ropivacaine infusion plus repeated daily boluses (Catheter group; standard care). They will be assessed for differences in the rate of postoperative complications, resources consumed with each intervention, as well as postoperative pain scores, opioid consumption, hospital and PACU length of stay, patient's satisfaction, and quality of recovery, and hospital length of stay.",[357,358,359,29],"Aortic Aneurysm, Abdominal","Abdominal Aortic Occlusion","Aortoiliac Occlusive Disease",[361,362,363,364,365,366],"Open abdominal aortic repair surgery","Rectus Sheath Block","Rectus Sheath Block and Catheter","Liposomal Bupivacaine","Exparel","Ropivacaine continuous infusion","2025-08-28",{"date":369,"type":48},"2025-09-03",{"date":371,"type":48},"2023-10-18",{"date":373,"type":21},"2026-12-30",{"name":375,"class":80},"Hartford Hospital",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":81},"100499009","management-of-aorto-iliac-infection-with-biointegral-surgical-no-react-bovine-pericardial-xenografts-100499009","NCT05777681","Management of Aorto-iliac Infection With BioIntegral Surgical No-React® Bovine Pericardial Xenografts","Inclusion Criteria:\n\n* Aortic infection\n* Mycotic Aneurysm\n* Aortic Graft Infection\n\nExclusion Criteria:\n\n* Absence of signs of infection",{"count":383,"type":21},30,"Aortic infections (AIs), including aortic graft infections (AGI) as well as mycotic aortic aneurysms (MAA), are rare. The aim of this study is to present our experience with xenogeneic aortic and aortoiliac reconstructions using the BioIntegral Surgical No-React® bovine pericardial graft.",[29],"2025-08-05",{"date":388,"type":48},"2025-08-11",{"date":390,"type":48},"2022-10-01",{"date":392,"type":21},"2026-11-01",{"name":125,"class":80},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":289,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":81},"100598218","korea-vhd-echo-study-surveillance-of-aortic-mitral--tricuspid-patients---insights-from-real-world-practice-100598218","NCT07068633","Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice","Inclusion Criteria:\n\n* Period: 2010.1.1\\~2020.12.31\n* Age \\> 18 years\n* Moderate or severe native VHD (AS, AR, MR and TR)\n* Perform echocardiography more than twice\n\nExclusion Criteria:\n\n* Poor image of echocardiography\n* Follow up loss",{"count":401,"type":21},30000,"Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions. However, there remains a significant lack of real-world data regarding echocardiography practices, disease prevalence and progression, referral patterns, and treatment pathways. Addressing these gaps is critical for improving patient care and informing clinical decision-making.\n\nSouth Korea provides a unique opportunity to conduct a nationwide retrospective echocardiographic study due to its advanced healthcare infrastructure, high patient volume, and strong tradition in clinical research. The current study aims to evaluate the real-world burden and clinical journey of patients with moderate or severe valvular disease over a 10-year period, based on echocardiographic and electronic medical record (EMR) data collected from multiple tertiary centers across the country.",[404,204,405,406,407,408,409,29],"Heart Valve Diseases","Aortic Valve Insufficiency","Mitral Valve Insufficiency","Mitral Valve Prolapse","Tricuspid Valve Insufficiency","Rheumatic Heart Disease","2025-07-07",{"date":412,"type":48},"2025-07-16",{"date":414,"type":21},"2025-08",{"date":416,"type":21},"2027-12-31",{"name":418,"class":80},"Yonsei University",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":429,"studyType":65,"phases":4,"briefSummary":430,"conditions":431,"keywords":440,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":450},"100404373","panther-study-of-terumo-aortic-knitted-and-woven-grafts-and-cardiovascular-patches-100404373","NCT04545502","PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","PANTHER","Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:\n\nAll Patients:\n\n* Patient meets the minimum age as per local regulations at time of consent\n* Patient requires treatment with study device(s) according to the IFU(s)\n* Patient is willing and able to comply with all SOC procedures and study visits\n* Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively\n\n  * For prospective emergency patients, retrospective consent is permissible\n  * For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.\n\nRetrospective Patients only:\n\n* Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.\n* Patient implant date is no more than 5 years prior to study start date.\n\nExclusion Criteria:\n\n* Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:\n\n  * Patient is unable or unwilling to comply with the SOC procedures or follow-up regime\n  * Patient is contraindicated per the device IFU\n  * Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure",{"count":428,"type":21},2000,"10 Years","The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.\n\nData will be collected both retrospectively and prospectively.",[432,433,434,435,436,437,438,439,29],"Aneurysm","Dissection","Aortic Root Aneurysm","Aortic Root Dissection","Carotid Artery Injuries","Aortic Arch","Bypass Extremity Graft","Occlusive Vascular Disease",[441],"Vascular Surgery","2025-05-28",{"date":444,"type":48},"2025-06-03",{"date":446,"type":48},"2021-02-17",{"date":448,"type":21},"2037-01",{"name":54,"class":55},31,{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":81},"100540587","concordance-of-three-imaging-methods-by-dynamic-ct-contrast-ultrasound-and-ct-angiography-in-the-characterization-of-endoleaks-in-patients-with-an-aortic-endoprosthesis-100540587","NCT06318780","Concordance of Three Imaging Methods by Dynamic CT, Contrast Ultrasound and CT Angiography in the Characterization of Endoleaks in Patients With an Aortic Endoprosthesis","LEAKDYN","Inclusion Criteria:\n\n* Patients 18 years of age and older,\n* Patients who have received EVAR ,\n* Detection of endoleak and\u002For with an aneurysmal sac enlargement greater than or equal to 5 mm over 6 months.\n\nExclusion Criteria:\n\n* Minor patients,\n* absence of endoleak and growth of the aneurysmal sac (greater than or equal to 5 mm over 6 months),\n* patient under guardianship, curators, safeguard of justice,\n* patient deprived of liberty,\n* pregnant woman\n* Patient who does not benefit from a social security scheme",{"count":459,"type":21},69,[24],"Among patients who have undergone EVAR, there is a significant risk of 20-50% endoleak. These endoleaks often require secondary interventions to reduce the risk of expansion or rupture. Currently, three-phase CT angiography and CEUS ultrasound are recommended in the post-operative monitoring of EVAR but these remain limited in characterizing the type and source of endoleak. In this study the investigators will study the interest of d-CTA for a better detection and characterization of endoleaks.",[29],[464,465,466],"EVAR","d-CTA","CEUS","2025-05-21",{"date":469,"type":48},"2025-05-25",{"date":471,"type":48},"2024-02-28",{"date":473,"type":21},"2031-02",{"name":475,"class":80},"Centre Hospitalier Universitaire, Amiens",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":81},"100583948","active-thoracic-compromised-distal-landing-in-tevar-100583948","NCT06882967","Active Thoracic Compromised Distal LANding in TEvar","Thoracic Endovascular Aortic Repair in Compromised Distal Landing Zones","ATLANTE","Inclusion Criteria:\n\n* Patients with descending thoracic aortic aneurysms (DTAAs) with a maximal aortic diameter \\> 55mm or rapid growth (\\>10mm \u002F year).\n* Patients presenting with at least 2 cognizable features related to an adverse aortic morphology will be considered for inclusion. The following features will be evaluated for the inclusion: distal LZ length ≤25-mm, distal LZ diameter ≥38-mm, LZ conical morphology, distal descending thoracic aorta angulation ≤116° or tortuosity index ≥1.4\n\nExclusion Criteria:\n\n* Emergency setting, including hemodynamic instability at time of enrollment\n* Patients with aortic dissection pathology",{"count":485,"type":21},200,"Thoracic endovascular aortic repair (TEVAR) has become the mainstay of aortic intervention for descending thoracic aortic pathology. Its durability hinges on achieving adequate seal in the endograft landing zones (LZs), with the distal LZ largely understudied. Only recently are suboptimal distal LZs receiving attention for their role in major complications including stent graft migration, type 1B endoleaks, and distal stent graft-induced new entry tears, all of which can contribute to further aortic degeneration. The thoracic distal LZ. When a short distal LZ was reported, the distal endoleak rate ranged from 3.5% to 33%. This led to reintervention in 19%, along with coverage of the celiac trunk in more than half of short LZ cases.\n\nThe objective of this study was to evaluate the outcomes of TEVAR patients with compromised distal landing zone (CDLZs) treated with distal active fixation stent-grafts (DAFs), distal scallop stent-grafts, distal Aptus Heli-FX EndoAnchors, and standard stent-grafts.",[488,29],"Thoracic Aortic Aneurysm","2025-03-15",{"date":491,"type":48},"2025-03-19",{"date":493,"type":48},"2022-11-01",{"date":495,"type":21},"2027-11-01",{"name":125,"class":80},{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":81},"100498992","mid--and-long-term-outcomes-of-custom-made-aortic-devices-100498992","NCT05777460","Mid- and Long-term Outcomes of Custom-made Aortic Devices","Results From a Multicenter Registry on the Outcomes of the Terumo Custom-made Aortic Endograft","Inclusion Criteria:\n\n* Thoracic Aortic Disease\n\nExclusion Criteria:\n\n* Urgent\u002FEmergent treatment",{"count":505,"type":21},60,"This study aims to evaluate mid- and long-term outcomes after Thoracic endovascular aortic repair (TEVAR) with custom-made devices.",[29,488],{"date":509,"type":48},"2025-03-18",{"date":511,"type":48},"2020-10-01",{"date":495,"type":21},{"name":125,"class":80},{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":81},"100498991","international-multicenter-mycotic-aneurysm-aorto-iliac-study-100498991","NCT05777447","International Multicenter Mycotic Aneurysm Aorto-iliac Study","Long Term Results of Aorto-iliac Mycotic Aneurysms","MAAI","Inclusion Criteria:\n\n* primary mycotic aorto-iliac aneurysm who underwent in situ repair\n\nExclusion Criteria:\n\n* patient with vascular graft infections;\n* patient with secondary aorto-enteric fistula.",{"count":225,"type":21},"The term mycotic aneurysm (MA) is commonly used to describe all infected aneurysms. Although MAs are believed to occur uncommonly, the true incidence is difficult to determine and is probably underestimated since MAs can be asymptomatic and are diagnosed only at autopsy. In an autoptic study, mycotic aortic aneurysms (MAAs) were reported in 3.3% of all detected aneurysms. The incidence of infected aneurysms of the aorta and iliac arteries ranges from 0.6% to 1.3%.\n\nA recent literature review of the management of MAAs showed that therapeutic strategies are multiple, including open surgical repair (OSR) in the majority of cases, endovascular aortic repair (EVAR), which increased over the last decade, and medical treatment alone for patients unfit for any aortic repair in a very limited part. Following the unfavorable prognosis towards rupture and since the medical treatment alone in mycotic aneurysms has shown mortality of almost 100%, surgical treatment is generally the preferred option.\n\nSurgical treatment includes both open and endovascular surgery. The latter is less invasive than conventional surgery but does not involve resection of the infected tissue and is therefore associated with an increased risk of sepsis and prosthesis infection. The gold standard is still open surgery, including extra-anatomic reconstruction and in situ repair, with different type of vascular graft.\n\nThis is a multicenter retrospective observational study. It will examine all patients undergoing surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction at the participating centers.",[525,29],"Mycotic Aneurysm",{"date":509,"type":48},{"date":528,"type":48},"2020-01-01",{"date":530,"type":21},"2027-01-01",{"name":125,"class":80},{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":541,"conditions":542,"keywords":546,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":81},"100555598","gastrointestinal-dysfunction-in-aortic-surgery-patients-100555598","NCT06514170","Gastrointestinal Dysfunction in Aortic Surgery Patients","Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.","Inclusion Criteria:\n\n* 18 years of age or older.\n* Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.\n* Invasive mechanical ventilation expected to be required more than 48 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under mechanical ventilation with pre-existing gastrointestinal issues.\n* Diagnosis of adult congenital heart disease.\n* Ongoing pregnancy or lactation period.\n* Simultaneous participation in another clinical study involving experimental therapy.\n* Presence of chronic intestinal disease.\n* Previous gastrointestinal conditions detected during nutritional screening.",{"count":540,"type":21},114,"The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary \\[calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)\\] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.",[27,543,29,544,545],"Gastrointestinal Dysfunction","Enteral Feeding Intolerance","Surgical Complication",[547,548,549],"Gastrointestinal dysfunction","Aortic diseases","Aorta surgery","2024-07-23",{"date":552,"type":48},"2024-07-24",{"date":550,"type":48},{"date":555,"type":21},"2026-06",{"name":557,"class":80},"Instituto Nacional de Cardiologia Ignacio Chavez",{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":81},"100531407","safety-and-efficacy-of-xj-procedure-in-patients-with-acute-type-a-aortic-dissection-surgery-100531407","NCT06199401","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery (ADVANCED-XJ-Ⅱ): A National, Multi-center, Open-label, Randomized, Controlled, Blinded-end Point Trial","ADVANCED-XJ-Ⅱ","Inclusion Criteria:\n\n* Age 18-70 years;\n* Patients with ATAAD attending the relevant department who have been assessed by a clinician as needing \"Sun's procedure\".\n\nExclusion Criteria:\n\n* Severe aortic root involvement (root diameter \\>45 mm, root tear, severe destruction of the aortic root, combined valve disease);\n* Combined coronary artery disease requiring concomitant coronary revascularization;\n* Prior aortic or cardiac surgery;\n* Preoperative severe malperfusion syndromes such as: severe cerebral complications (acute cerebral infarction, cerebral hemorrhage, coma, etc.); malperfusion of abdominal organs or lower extremities \\>12 h;\n* Preoperative combination of severe single or multiple organ failure;\n* Pregnant women;\n* Refused to sign the informed consent form and refused to participate in this study.",{"count":567,"type":21},680,[24],"This is a national, multicenter, open-label, randomized, controlled, endpoint-blinded clinical trial of patients diagnosed with ATAAD and undergoing \"Sun's procedure\" coordinated by the First Affiliated Hospital of Xi'an Jiaotong University, China. Per the protocol, \"Sun's procedure\" combined with \"XJ-Procedure\" in the anastomosis of the aortic root and Sun's procedure combined with regular suturing methods of the aortic root will be compared.",[571,572,29],"Type A Aortic Dissection","Complication of Surgical Procedure",[571,574,575,576],"Aortic Root Reinforcement","Cardiovascular Surgery","Postoperative Complication","2024-07-10",{"date":579,"type":48},"2024-07-12",{"date":581,"type":48},"2024-01-11",{"date":583,"type":21},"2027-12-01",{"name":585,"class":80},"First Affiliated Hospital Xi'an Jiaotong University",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":593,"enrollmentInfo":594,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":81},"100543621","standardized-physician-modified-fenestrated-endograft-registry-100543621","NCT06358248","Standardized Physician-modified Fenestrated Endograft Registry","SPHERE","INCLUSION CRITERIA\n\n* Complex AAA (including short-neck AAA, JRAA, PRAA, extent IV TAAA)\n* Haemodynamic stability\n* Anatomical feasibility is based on the presence of a proximal aortic neck above the mid celiac trunk of ≥25 mm in length and between 18 mm and 35 mm in diameter; the neck needs to be \"healthy\" with no parietal calcifications or thrombus with a cylindrical shape. The visceral aorta is required to be no larger than 40 mm in maximum diameter.\n\nEXCLUSION CRITERIA\n\n* Extent I-III TAAA\n* Hemorrhagic shock","100 Years",{"count":595,"type":21},50,"Multicenter retrospective study including all consecutive patients treated by PMEG using a standard modification technique of Valiant Captivia (Medtronic, Minneapolis, MN-USA).",[598,29],"Aortic Aneurysm, Thoracoabdominal",[27,600,601],"Thoracoabdominal Aneurysm","Endovascular aortic repair","2024-04-13",{"date":604,"type":48},"2024-04-16",{"date":606,"type":48},"2023-10-01",{"date":608,"type":21},"2033-10-01",{"name":610,"class":80},"University Hospital Padova",{"id":612,"slug":613,"hasResults":11,"nctId":614,"briefTitle":615,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":352},"100513152","registry-of-multicenter-brain-heart-comorbidity-in-china-100513152","NCT05961748","Registry of Multicenter Brain-Heart Comorbidity in China","BHC-C","Inclusion Criteria:\n\n* age \\> 18 years old\n* Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nExclusion Criteria:\n\n·refuse to participate in the registry",{"count":619,"type":21},100000,"This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale \"brain-heart comorbidity\" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.\n\nAny of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nThe data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http:\u002F\u002F10.100.101.65:30080\u002Flogin).",[171,622,176,170,29,623,624,625,626,627,628,629,630],"Cardiac Arrest","Subarachnoid Hemorrhage","Intracerebral Hemorrhage","Cerebral Infarction","Occlusion and Stenosis of Precerebral Arteries","Occlusion and Stenosis of Cerebellar Arteries","Cerebral Aneurysm","Moyamoya Disease","Arteriovenous Malformation of Cerebral Vessels","2023-09-16",{"date":633,"type":48},"2023-09-21",{"date":635,"type":48},"2012-01-01",{"date":637,"type":21},"2032-12-31",{"name":639,"class":80},"Beijing Tiantan Hospital",{"id":641,"slug":642,"hasResults":11,"nctId":643,"briefTitle":644,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":646,"enrollmentInfo":647,"targetDuration":649,"studyType":65,"phases":4,"briefSummary":650,"conditions":651,"keywords":657,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":668,"locationsCount":81},"100463055","endobarc-s-study-endovascular-branched-stent-grafts-for-aortic-arch-pathologies-in-spain-100463055","NCT05309707","ENDOBARC-S Study: \"Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain\"","Inclusion Criteria:\n\n* Patient is between 18 and 90 years old\n* Patient with aortic arch pathologies (aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma), treated by branched stent-grafts (Nexus stent graft system©, Relay® Branch or Zenith arch branch graft®, with proximal landing at zone 0.\n* Patient must be available for the appropriate follow-up times for the duration of the study\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Patient less than 18 years old or more than 90 years old.\n* Patient has allergies to materials necessary for endovascular repair (e.g. contrast media, anticoagulants or heparin, nitinol, polyester, gold, platinum-iridium)\n* Patient has systemic infection or suspected systemic infection\n* Patient has thrombocytopenia (platelet count \\\u003C 150000\u002Fµl)\n* Patient has untreated hyperthyroidism\n* Patient has a progressive or untreated malignancy.\n* Patient is pregnant or breastfeeding.\n* Patient has a life expectancy of less than 1 year.\n* Not informed consent signed","90 Years",{"count":648,"type":21},100,"5 Years","The ENDOBARC-S post-market clinical follow-up study is undertaken to evaluate the prevention of death related to aortic arch pathologies when treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.\n\nThe secondary objective is to evaluate the safety and clinical performance of the studied devices.",[488,652,653,654,655,29,169,656],"Thoracic Aortic Dissection","Stent-Graft Endoleak","Stent-Graft Stenosis","Intramural Hematoma","Vascular Diseases",[658,659,660,661],"Aorta","Thoracic aortic aneurysm","Thoracic aorta dissection","Endovascular repair","2022-03-24",{"date":664,"type":48},"2022-04-04",{"date":666,"type":48},"2022-01-01",{"date":416,"type":21},{"name":669,"class":670},"Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","NETWORK"]